[Sanofi Q3 2026 Earnings Call] Sanofi Lifts 2026 Guidance as Dupixent Tops €5.7 Billion, but Braces for 2027 Price Reset and €1.3 Billion Divestment Hit
Sanofi raised its 2026 guidance after Q3 sales reached €14.4B, up 14.3% YoY, driven by Dupixent's €5.7B performance. Management warned of a tougher 2027 due to pricing headwinds and €1.3B divestment impact. Dupixent's growth is expected to moderate, but the company reaffirmed its €25B peak sales target by 2030.
How this was made
The 30-second read
Why it matters
The guidance lift is a primary disclosure that can shift valuation models and analyst forecasts.
Market read
Guidance upgrade provides fresh material for traders; the stock may rally on the news.
What to watch
Potential competition for Dupixent and the upcoming price reset may limit long‑term growth.
Background
Sanofi reported Q3 2026 results, highlighted strong Dupixent sales, and updated full‑year guidance.
Ticker impact
Sanofi raised its 2026 sales and EPS guidance after Q3 earnings, providing new growth expectations.
likely upward pressure as the market prices in higher growth expectations
The company announced 13-15% sales growth and 15-17% EPS growth for 2026, a material improvement over prior outlook.
Market effects
Higher guidance may lift the broader pharma/biotech sector as peers are re‑rated.
European markets could see a modest boost from Sanofi's outlook.
Sanofi's guidance influences global healthcare sentiment given its size.
Counterpoint
The 2027 pricing headwind and divestment impact could temper upside, suggesting caution.
Key entities
- CompanySanofi
French multinational pharmaceutical firm.
